Atlantic Trust LLC Buys Shares of 624 Stryker Co. (SYK)

Atlantic Trust LLC purchased a new stake in shares of Stryker Co. (NYSE:SYK) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 624 shares of the medical technology company’s stock, valued at approximately $105,000.

A number of other institutional investors also recently modified their holdings of the business. BlackRock Inc. increased its stake in Stryker by 2.7% during the 2nd quarter. BlackRock Inc. now owns 24,551,677 shares of the medical technology company’s stock valued at $4,145,795,000 after purchasing an additional 646,505 shares in the last quarter. FMR LLC increased its stake in Stryker by 24.0% during the 2nd quarter. FMR LLC now owns 5,327,862 shares of the medical technology company’s stock valued at $899,662,000 after purchasing an additional 1,032,333 shares in the last quarter. Morgan Stanley increased its stake in Stryker by 7.3% during the 2nd quarter. Morgan Stanley now owns 2,305,235 shares of the medical technology company’s stock valued at $389,262,000 after purchasing an additional 157,400 shares in the last quarter. Wells Fargo & Company MN increased its stake in Stryker by 3.2% during the 2nd quarter. Wells Fargo & Company MN now owns 2,037,752 shares of the medical technology company’s stock valued at $344,094,000 after purchasing an additional 63,251 shares in the last quarter. Finally, Carmignac Gestion increased its stake in Stryker by 36.6% during the 1st quarter. Carmignac Gestion now owns 1,599,867 shares of the medical technology company’s stock valued at $257,451,000 after purchasing an additional 428,789 shares in the last quarter. Institutional investors and hedge funds own 75.08% of the company’s stock.

NYSE:SYK opened at $169.88 on Tuesday. The firm has a market capitalization of $64.81 billion, a PE ratio of 26.30, a price-to-earnings-growth ratio of 2.43 and a beta of 0.59. Stryker Co. has a 1-year low of $138.94 and a 1-year high of $179.84. The company has a current ratio of 1.83, a quick ratio of 1.15 and a debt-to-equity ratio of 0.63.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, July 24th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.73 by $0.03. Stryker had a net margin of 8.28% and a return on equity of 26.93%. The firm had revenue of $3.32 billion for the quarter, compared to the consensus estimate of $3.31 billion. During the same period in the prior year, the firm posted $1.53 earnings per share. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. research analysts predict that Stryker Co. will post 7.25 EPS for the current fiscal year.

A number of brokerages have issued reports on SYK. Zacks Investment Research upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $196.00 price target on the stock in a research note on Friday, June 1st. BMO Capital Markets restated a “hold” rating and set a $174.00 price target on shares of Stryker in a research note on Thursday, July 12th. JPMorgan Chase & Co. upped their price target on shares of Stryker to $200.00 and gave the company an “overweight” rating in a research note on Thursday, September 13th. Royal Bank of Canada restated a “buy” rating and set a $184.00 price target on shares of Stryker in a research note on Wednesday, July 25th. Finally, Canaccord Genuity restated a “buy” rating and set a $185.00 price target on shares of Stryker in a research note on Wednesday, July 25th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $178.33.

In related news, VP Katherine Ann Owen sold 37,866 shares of the stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $166.84, for a total transaction of $6,317,563.44. Following the sale, the vice president now directly owns 11,367 shares of the company’s stock, valued at $1,896,470.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.40% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: Tariff

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply